Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Invetx

Explore full profile

Bringing the best of biopharma to animal health through closing the innovation gap between animal and human biotechnology

Boston, United StatesFounded 2018Biotech & Life Sciences
Valuation $500M–1B Last recorded · 2024
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Invetx and the history behind them.

About Invetx

Invetx is a pioneering startup operating in the biotechnology sector, specifically focusing on animal health. The company's primary objective is to develop protein-based therapeutics for veterinary care, which is a novel approach in the industry. Invetx's target market includes both pets and farm animals, with a dual focus on improving veterinary care and promoting sustainable health and productivity in farm animals.

The company operates by partnering with leading biotechnology firms, leveraging their expertise and capabilities to discover and develop advanced veterinary biotherapeutics. This collaborative business model allows Invetx to tap into a wealth of knowledge and resources, thereby accelerating the development of innovative therapies.

Invetx's revenue model is likely based on the commercialization of these therapies. Once a therapy is developed and approved, it can be sold to veterinary clinics, animal health companies, and potentially directly to pet owners or farmers. The company's unique cross-disciplinary team, which includes R&D leaders from both human biotech and animal health sectors, positions it well to deliver on its ambitious goals.

Invetx is based in Boston, MA, and is backed by dedicated investors. This financial support, combined with the company's extensive network of industry experts and close collaboration with veterinary scientists and clinicians, makes it an attractive partner for other companies and experts in the field.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2018
Headquarters
Boston, United States
Employees
9
Open positions
None listed
Dealroom signal
64.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jul 2024 $520M $520M Dechra Pharmaceuticals ↗
SERIES BOther financing May 2022 $61M $242M Anterra Capital · Tekla Capital Management · Novo Holdings · F-Prime ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Invetx website traffic

Latest recorded traffic for Invetx is 910 monthly website visits, down 52.1% over the last three months. Invetx's team declined 52.6% over the past year.

Latest monthly visits910 3-month web change-52.1% 1-year team growth-52.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Other known investors1 additional known investor

  • Dechra Pharmaceuticals
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Invetx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Invetx’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.